Phoenix Financial Ltd. Has $949,000 Stake in Brainsway Ltd. Sponsored ADR $BWAY

Phoenix Financial Ltd. trimmed its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 82.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the company’s stock after selling 299,316 shares during the period. Phoenix Financial Ltd. owned about 0.33% of Brainsway worth $949,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BWAY. Raymond James Financial Inc. acquired a new position in Brainsway during the second quarter valued at approximately $85,000. NewEdge Advisors LLC boosted its holdings in shares of Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after buying an additional 7,549 shares during the last quarter. Huntleigh Advisors Inc. grew its stake in shares of Brainsway by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock valued at $1,018,000 after buying an additional 4,143 shares in the last quarter. Eagle Global Advisors LLC grew its stake in shares of Brainsway by 19.3% in the third quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company’s stock valued at $1,120,000 after buying an additional 12,000 shares in the last quarter. Finally, ARK Investment Management LLC increased its holdings in Brainsway by 6.1% during the second quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock worth $2,628,000 after buying an additional 11,498 shares during the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

Brainsway Price Performance

Shares of NASDAQ BWAY opened at $25.61 on Wednesday. The firm has a market cap of $501.44 million, a price-to-earnings ratio of 85.37 and a beta of 1.19. The stock’s fifty day moving average price is $19.29 and its two-hundred day moving average price is $16.31. Brainsway Ltd. Sponsored ADR has a one year low of $7.84 and a one year high of $25.64.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The business had revenue of $13.51 million during the quarter, compared to the consensus estimate of $13.04 million. Brainsway had a net margin of 12.73% and a return on equity of 9.46%. On average, equities analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. HC Wainwright increased their price target on shares of Brainsway from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Monday. Northland Securities set a $30.00 target price on shares of Brainsway in a research note on Thursday, January 22nd. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Brainsway currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.